Plain-English translation of NCT07631000 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new approach to treating stomach cancer and gastroesophageal junction cancer (a type of cancer where the stomach meets the esophagus). The trial combines a medication called —which helps your immune system fight cancer—with standard chemotherapy drugs. Researchers want to see if adding to the usual chemotherapy makes treatment more effective and is safe for patients whose cancer can be surgically removed.
Currently, standard chemotherapy is the main treatment given before surgery for these types of stomach cancer. However, some patients do not respond well enough to chemotherapy alone. This medication works by helping your body's own immune system recognize and attack cancer cells, so the goal is to see if this combination approach can improve outcomes and give patients a better chance of recovery.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive combined with standard chemotherapy (FLOT) before your surgery. You will attend regular clinic visits for treatment administration and monitoring, and you'll have blood tests and tumor biopsies taken at specific timepoints to check how well the medication is working and how your body is tolerating it. After completing the medication phase, you will have surgery to remove the cancer, as planned. The study involves about 37 participants and is being run by Memorial Sloan Kettering Cancer Center.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
United States